Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

October 25, 2024

Massimo Cristofanilli, MD, discusses the use of circulating tumor DNA for minimal residual disease detection in patients with breast cancer.

October 16, 2024

Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.

October 10, 2024

Justin Kaner, MD, discusses the latest advances surrounding menin inhibitors in acute myeloid leukemia.

August 13, 2024

The panel concludes its discussion with a look to the future of CLL treatment, focusing on emerging novel agents and exciting clinical research.

August 06, 2024

Highlighting recent clinical trial data on pirtobrutinib in patients with chronic lymphocytic leukemia, the panel shares their experience utilizing it in clinical practice.

August 06, 2024

Bita Fakhri, MD, MPH, shares her general approach to managing common cardiovascular adverse events associated with BTK inhibitors in patients with chronic lymphocytic leukemia.

July 30, 2024

The panel addresses the intricacies of treating patients with chronic lymphocytic leukemia who experience treatment resistance.

July 30, 2024

Experts on chronic lymphocytic leukemia discuss treatment practices for patients with relapsed/refractory CLL and provide insights on the role for venetoclax in patients who previously received BTK inhibitors.

July 23, 2024

A hematology and oncology specialist presents the case of a 66-year-old man with chronic lymphocytic leukemia.

July 23, 2024

Catherine C. Coombs, MD, outlines considerations for long-term treatment planning, particularly in younger patients with chronic lymphocytic leukemia.

July 16, 2024

John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.

July 16, 2024

Bita Fakhri, MD, MPH, discusses the importance of patient involvement in the shared decision-making process to individualize treatment and improve outcomes.

July 09, 2024

Experts on chronic lymphocytic leukemia detail how clinical trial data on doublet therapies help inform treatment decisions in the first line.

July 09, 2024

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.

July 04, 2024

Pooja Murthy, MD, discusses second-line treatments in ER+/HER2– metastatic breast cancer for patients following progression on endocrine therapy plus a CDK4/6 inhibitor.

July 03, 2024

Catherine C. Coombs, MD, discusses the value of real-world data in informing the treatment of patients with chronic lymphocytic leukemia.

July 03, 2024

John N. Allan, MD, describes how he selects patients for first-line treatment with continuous BTK inhibitor therapy, referencing data from the RESONATE-2, ELEVATE-TN, and SEQUOIA studies.

June 25, 2024

Bita Fakhri, MD, MPH, outlines factors she considers when choosing between fixed-duration and continuous BTK inhibitor therapy and discusses how she approaches treatment discussions with patients.

June 25, 2024

A panel of experts on chronic lymphocytic leukemia (CLL) review a patient case and describe their initial impressions on treatment decisions.

May 08, 2024

Cytoreductive therapy with rIFNα or hydroxyurea is safe and well tolerated in patients with polycythemia vera under the age of 60 years.